Search PubMed⌕ Search

Biomedical subjects

M Harada

Publications and source records attributed to M Harada.

At least 1,171 records · Page 65Linked to original sources
PubMed1983

[Autologous bone marrow transplantation in the treatment of nasopharyngeal carcinoma--report of 2 cases].

Two patients with nasopharyngeal carcinoma (NPC) were treated with "marrow-lethal" chemoradiotherapy and infusion of cryopreserved autologous marrow. Patient AUT 04 (unique patient number), a 28-year-old male, was referred to us because of the right cervical lymphadenopathy. He was diagnosed NPC at stage II (T1N2M0). A trial of combined-modality therapy using autologous bone marrow transplantation (auto-BMT) was scheduled for possible cure. Before auto-BMT, he was treated with a conventional dose of radiation to the nasopharyngeal and bilateral cervical areas. For the pretransplant marrow-lethal therapy, he received high-dose cyclophosphamide (CY), 120mg/kg, and 1,000 rad total body irradiation (TBI). Within 24 hr after TBI, previously cryopreserved-thawed autologous bone marrow cells (1.37 X 10(8)/kg) was infused to the patient. Rapid and complete hematologic recovery was observed and he is now alive in a disease-free remission state 28 months after transplantation. Patient AUT 08, a 18-year-old female, was referred to us for the treatment of head and neck tumor with auto-BMT. She was diagnosed NPC at stage IV (T4N2M0). After cryopreservation of bone marrow, she was treated with local radiation and doxorubicin (80mg X 2d). Then she was conditioned with high-dose CY and upper half body irradiation and received auto-BMT (marrow dose: 1.2 X 10(7)/kg). Successful engraftment was obtained with tumor response but she developed recurrence of the disease 12 months after transplantation. Although the data are too preliminary, auto-BMT is evaluated as one of the favorable treatment approaches for some selected patients with NPC.

Adolescent↗
PubMed1983

Hematologic recovery following autologous and allogeneic bone marrow transplantation.

Posttransplant hematologic recovery was compared between 9 autologous and 11 allogeneic marrow transplant patients who received similar marrow-lethal chemoradiotherapies before transplantation. Although the autotransplant patients were infused with much lower marrow doses compared with the allotransplant patients, they showed adequate hematologic recovery with acceptable risk. Regardless of marrow doses, delayed platelet recovery and failure of platelet recovery were observed in 7 patients. All of these patients experienced early transplantation-related complications before engraftment. Despite the limited number of patients, a number of myeloid progenitor cells (CFUC) infused correlated significantly with the period for recovery of polymorphonuclear cells in autologous marrow recipients while there was no significant correlation found between marrow dose and hematologic recovery in both groups of patients. Furthermore, autotransplant patients showed a characteristic recovery pattern of peripheral blood lymphocytes in an early posttransplant period, whic was not observed in allotransplant patients.

Acute Disease↗
PubMed1983

[Comparative double-blind study of cefroxadine and cephalexin in the treatment of complicated urinary tract infection].

To evaluate the efficacy, safety, and utility of cefroxadine (CXD) for the treatment of complicated urinary tract infections, a double blind study comparing CXD with cephalexin (CEX) was carried out. Patient received either 1,500 mg/day of CXD 3 times a day, or 2,000 mg/day of CEX 4 times a day for 5 days by oral route, and the following results were obtained. Of the 305 patients, clinical efficacies were evaluated in 220 cases (CXD 105 cases, CEX 115 cases) except that excluded or dropped out. Side effect was evaluated in 301 cases (CXD 150 cases, CEX 151 cases). There was no statistically significant difference in the back ground characteristics between the 2 groups. Overall clinical assessment by the committee according to the "Criteria for Evaluation of Clinical Efficacy of Antimicrobial Agents on Urinary Tract Infection" patients evaluated as better than "good" were 64 of 105 (61.0%) for CXD and 75 of 115 (65.2%) for CEX. The difference between the 2 groups was not statistically significant. In effect on pyuria, patients evaluated as better than "decreased" were 58 of 105 (55.2%) for CXD and 69 of 115 (60.0%) for CEX. The difference between the 2 groups was not statistically significant. In effect of bacteriuria, patients evaluated as better than "decreased" were 57 of 105 (54.3%) for CXD and 69 of 115 (60.0%) for CEX. The difference between the 2 groups was not statistically significant. Analyses were stratified according to classification by the type of infection, diagnosis, degree of pyuria before treatment, and bacterial count before treatment. There were no statistically significant differences between the 2 treatment groups as to any item. In evaluation by attending physician, patients evaluated as better than "good" were 81 of 140 (57.9%) for CXD, and 85 of 141 (60.3%) for CEX. Statistically significant difference was not observed between the 2 groups. In drug usefulness by attending physician, patients evaluated as better than "usefulness" were 106 of 140 (75.7%) for CXD, and 109 of 141 (77.3%) for CEX. The difference between the 2 groups was not statistically significant. In evaluation of the infections with sensitive species to both CXD and CEX by the committee according to "Criteria for Evaluation of Clinical Efficacy of Antimicrobial Agents on Urinary Tract Infections, overall clinical efficacies were evaluated in 102 (CXD 48 cases, CEX 54 cases) which were infected with sensitive species. There was no statistically significant difference in the back ground characteristics between the 2 treatment groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Adult↗